The HPV vaccine is the only vaccine that prevents several types of cancer, including cervical cancer. It is safe and effective, and the elimination of cervical cancer is within reach. However, HPV vaccine uptake in the US is too low to achieve herd immunity. In 2023, 57.3% of adolescents aged 13-15 years received the recommended 2 or 3 doses of the vaccine. Vaccination coverage dropped to 61.4% in 2023, down from 62.6% in 2022.[1][2][7] Goals such as 80% vaccination of adolescents up to the age of 13 by 2026 have not yet been met.[6][8] Despite this, sales of the vaccine in the US are increasing.[2]